115 related articles for article (PubMed ID: 10757896)
1. Delay of onset of candidemia and emergence of Candida krusei fungemia in hematologic patients receiving prophylactic fluconazole.
Jarque I; Saavedra S; Martin G; Pemán J; Pérez Bellés C; Sanz MA
Haematologica; 2000 Apr; 85(4):441-3. PubMed ID: 10757896
[No Abstract] [Full Text] [Related]
2. Candida glabrata and Candida krusei fungemia after high-risk allogeneic marrow transplantation: no adverse effect of low-dose fluconazole prophylaxis on incidence and outcome.
Safdar A; van Rhee F; Henslee-Downey JP; Singhal S; Mehta J
Bone Marrow Transplant; 2001 Nov; 28(9):873-8. PubMed ID: 11781648
[TBL] [Abstract][Full Text] [Related]
3. The changing epidemiology of invasive candidiasis: Candida glabrata and Candida krusei as the leading causes of candidemia in hematologic malignancy.
Hachem R; Hanna H; Kontoyiannis D; Jiang Y; Raad I
Cancer; 2008 Jun; 112(11):2493-9. PubMed ID: 18412153
[TBL] [Abstract][Full Text] [Related]
4. Candidemia in patients with hematologic malignancies in the era of new antifungal agents (2001-2007): stable incidence but changing epidemiology of a still frequently lethal infection.
Sipsas NV; Lewis RE; Tarrand J; Hachem R; Rolston KV; Raad II; Kontoyiannis DP
Cancer; 2009 Oct; 115(20):4745-52. PubMed ID: 19634156
[TBL] [Abstract][Full Text] [Related]
5. Breakthrough fungemia caused by fluconazole-resistant Candida albicans with decreased susceptibility to voriconazole in patients with hematologic malignancies.
Myoken Y; Kyo T; Sugata T; Murayama SY; Mikami Y
Haematologica; 2006 Feb; 91(2):287-8. PubMed ID: 16461328
[TBL] [Abstract][Full Text] [Related]
6. Clinical significance of breakthrough fungemia caused by azole-resistant Candida tropicalis in patients with hematologic malignancies.
Myoken Y; Kyo T; Fujihara M; Sugata T; Mikami Y
Haematologica; 2004 Mar; 89(3):378-80. PubMed ID: 15020289
[TBL] [Abstract][Full Text] [Related]
7. Candidemia in patients with hematologic malignancies: analysis of 7 years' experience in a single center.
Vigouroux S; Morin O; Moreau P; Harousseau JL; Milpied N
Haematologica; 2006 May; 91(5):717-8. PubMed ID: 16670081
[TBL] [Abstract][Full Text] [Related]
8. Fungal colonization and invasive fungal infections following allogeneic BMT using metronidazole, ciprofloxacin and fluconazole or ciprofloxacin and fluconazole as intestinal decontamination.
Trenschel R; Peceny R; Runde V; Elmaagacli A; Dermoumi H; Heintschel von Heinegg E; Müller KD; Schaefer UW; Beelen DW
Bone Marrow Transplant; 2000 Nov; 26(9):993-7. PubMed ID: 11100279
[TBL] [Abstract][Full Text] [Related]
9. Fluconazole prophylaxis in extremely low birth weight neonates reduces invasive candidiasis mortality rates without emergence of fluconazole-resistant Candida species.
Healy CM; Campbell JR; Zaccaria E; Baker CJ
Pediatrics; 2008 Apr; 121(4):703-10. PubMed ID: 18381534
[TBL] [Abstract][Full Text] [Related]
10. The epidemiology of Candida colonization and invasive candidiasis in a surgical intensive care unit where fluconazole prophylaxis is utilized: follow-up to a randomized clinical trial.
Magill SS; Swoboda SM; Shields CE; Colantuoni EA; Fothergill AW; Merz WG; Lipsett PA; Hendrix CW
Ann Surg; 2009 Apr; 249(4):657-65. PubMed ID: 19300221
[TBL] [Abstract][Full Text] [Related]
11. Antifungal prophylaxis in neutropenic patients with hematologic malignancies.
Böhme A; Karthaus M; Hoelzer D
Antibiot Chemother (1971); 2000; 50():69-78. PubMed ID: 10874456
[No Abstract] [Full Text] [Related]
12. Candidemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after the adoption of prophylactic fluconazole.
Marr KA; Seidel K; White TC; Bowden RA
J Infect Dis; 2000 Jan; 181(1):309-16. PubMed ID: 10608780
[TBL] [Abstract][Full Text] [Related]
13. [Surveillance and prevention of invasive candidiasis in oncohematology].
Vescia N; Chierichini A; Mastroeni I
Ann Ig; 2000; 12(4 Suppl 2):103-9. PubMed ID: 11100559
[No Abstract] [Full Text] [Related]
14. [Candidemia: a never ceasing challenge].
Muñoz García de Paredes P
Rev Clin Esp; 1997 Dec; 197(12):795-7. PubMed ID: 9477668
[No Abstract] [Full Text] [Related]
15. Fluconazole use as an important risk factor in the emergence of fluconazole-resistant Candida glabrata fungemia.
Tumbarello M; Posteraro B; Trecarichi EM; Sanguinetti M
Arch Intern Med; 2009 Aug; 169(15):1444-5; author reply 1445. PubMed ID: 19667313
[No Abstract] [Full Text] [Related]
16. [Impact of antifungal prophylaxis on the gastrointestinal yeast colonisation in patients with haematological malignancies].
Rimek D; Redetzke K; Kappe R
Mycoses; 2006; 49 Suppl 2():18-23. PubMed ID: 17022757
[TBL] [Abstract][Full Text] [Related]
17. Breakthrough C. parapsilosis and C. guilliermondii blood stream infections in allogeneic hematopoietic stem cell transplant recipients receiving long-term caspofungin therapy.
Kabbara N; Lacroix C; Peffault de Latour R; Socié G; Ghannoum M; Ribaud P
Haematologica; 2008 Apr; 93(4):639-40. PubMed ID: 18379015
[No Abstract] [Full Text] [Related]
18. A retrospective Evaluation of fluconazole for the treatment of Candida glabrata fungemia.
Wilson AG; Micek ST; Ritchie DJ
Clin Ther; 2005 Aug; 27(8):1228-37. PubMed ID: 16199247
[TBL] [Abstract][Full Text] [Related]
19. Caspofungin-resistant Candida tropicalis strains causing breakthrough fungemia in patients at high risk for hematologic malignancies.
Garcia-Effron G; Kontoyiannis DP; Lewis RE; Perlin DS
Antimicrob Agents Chemother; 2008 Nov; 52(11):4181-3. PubMed ID: 18794386
[TBL] [Abstract][Full Text] [Related]
20. Candidemia in nonneutropenic critically ill patients: risk factors for non-albicans Candida spp.
Playford EG; Marriott D; Nguyen Q; Chen S; Ellis D; Slavin M; Sorrell TC
Crit Care Med; 2008 Jul; 36(7):2034-9. PubMed ID: 18552700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
